Search Results for "block"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for block. Results 191 to 200 of 328 total matches.
Second-Generation Antipsychotics - Aripiprazole Revisited
The Medical Letter on Drugs and Therapeutics • Oct 10, 2005 (Issue 1219)
, it blocks serotonin 2A (5-HT
2A
) receptors and, like ziprasidone, stimulates the 5-HT
1A
receptor ...
Aripiprazole (Abilify - Bristol-Myers Squibb/Otsuka), a second-generation (atypical) antipsychotic drug, was approved by the FDA in 2002 for treatment of schizophrenia and more recently for bipolar disorder as well. It has been promoted as causing fewer adverse effects than other antipsychotics, without sacrificing efficacy.
Etravirine (Intelence) for HIV Infection
The Medical Letter on Drugs and Therapeutics • Jun 16, 2008 (Issue 1288)
and other antiretroviral
agents.
1
MECHANISM OF ACTION — Etravirine binds directly
to reverse transcriptase and blocks ...
Etravirine (Intelence - Tibotec), a new non-nucleoside reverse transcriptase inhibitor (NNRTI), has received fast-track FDA approval for use in combination therapy in treatment-experienced adults who have HIV-1 infection resistant to an NNRTI and other antiretroviral agents.
Dimethyl Fumarate (Tecfidera) for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Jun 10, 2013 (Issue 1418)
– Gilenya Transaminase elevations, bradycardia, C 0.5 mg PO once daily 60,423.00
(Novartis) AV block ...
The FDA has approved dimethyl fumarate (Tecfidera –
Biogen Idec), formerly called BG-12, for treatment of
relapsing forms of multiple sclerosis (MS). It is the
third oral drug to be approved in recent years for this
indication.
Vedolizumab (Entyvio) for Inflammatory Bowel Disease
The Medical Letter on Drugs and Therapeutics • Sep 15, 2014 (Issue 1451)
natalizumab, which blocks lymphocyte
migration in the brain and gut by inhibiting 4β1
and 4β7 integrins ...
The FDA has approved vedolizumab (Entyvio - Takeda),
an intravenous integrin receptor antagonist, for treatment
of moderate to severe ulcerative colitis or Crohn's
disease in adults who have not responded to, lost
response to, or cannot tolerate standard treatment.
Natalizumab (Tysabri), another integrin receptor antagonist,
has been available for several years for treatment
of Crohn's disease and multiple sclerosis.
Tavaborole Topical Solution (Kerydin) for Onychomycosis
The Medical Letter on Drugs and Therapeutics • Mar 02, 2015 (Issue 1463)
PHARMACOLOGY — Tavaborole blocks fungal protein
synthesis by inhibiting aminoacyl-transfer ribonucleic
acid ...
The FDA has approved tavaborole 5% solution
(Kerydin – Anacor Pharmaceuticals) for topical treatment
of toenail onychomycosis due to Trichophyton
rubrum or Trichophyton mentagrophytes. It is the
first oxaborole antifungal drug to be approved for this
indication.
Idelalisib (Zydelig) for Chronic Lymphocytic Leukemia and Non-Hodgkins Lymphoma (online only)
The Medical Letter on Drugs and Therapeutics • May 11, 2015 (Issue 1468)
proliferation
of malignant B-cells and primary tumor cells
and inducing apoptosis. Blocking PI3Kδ inhibits ...
The FDA has approved idelalisib (Zydelig – Gilead),
an oral kinase inhibitor, for use in combination with
rituximab (Rituxan) for treatment of relapsed chronic
lymphocytic leukemia (CLL). It is also approved as
monotherapy for treatment of relapsed follicular
lymphoma and relapsed small lymphocytic lymphoma
(both are subtypes of indolent non-Hodgkins
lymphoma) in patients who have received at least two
prior systemic therapies.
In Brief: Two Drugs for Soft-Tissue Sarcoma (online only)
The Medical Letter on Drugs and Therapeutics • May 09, 2016 (Issue 1494)
transcription and blocks
DNA repair proteins to achieve an antiproliferative effect.2
It has not been shown ...
The anthracycline doxorubicin with or without the alkylating agent ifosfamide is the standard first-line treatment for advanced soft-tissue sarcomas. The FDA recently approved the minor groove DNA intercalator trabectedin (Yondelis – Janssen) for treatment of unresectable or metastatic liposarcoma or leiomyosarcoma in patients previously treated with an anthracycline. Trabectedin has been available for years in Europe for treatment of advanced soft-tissue sarcoma. The FDA has also approved the microtubule inhibitor eribulin mesylate (Halaven – Eisai), which was approved earlier for...
Reslizumab (Cinqair) for Severe Eosinophilic Asthma
The Medical Letter on Drugs and Therapeutics • Jun 20, 2016 (Issue 1497)
,
and activation of eosinophils. Reslizumab binds to IL-5,
blocking its binding to IL-5 receptors on the surface ...
The FDA has approved reslizumab (Cinqair – Teva), a
humanized interleukin-5 (IL-5) antagonist monoclonal
antibody, for add-on maintenance treatment of severe
asthma in adults who have an eosinophilic phenotype.
It is the second IL-5 antagonist to be approved in the
US; mepolizumab (Nucala) was approved for the same
indication in 2015.
Pembrolizumab (Keytruda) for First-Line Treatment of Metastatic NSCLC
The Medical Letter on Drugs and Therapeutics • Jan 30, 2017 (Issue 1513)
that binds to the PD-1 receptor,
blocking the interaction of PD-1 with its ligands and
promoting antitumor ...
The FDA has approved the immune checkpoint inhibitor
pembrolizumab (Keytruda – Merck), a programmed
death receptor-1 (PD-1) inhibitor, for first-line treatment
of patients with metastatic non-small cell lung cancer
(NSCLC) that highly expresses programmed death-ligand
1 (PD-L1) and has no epidermal growth factor
receptor (EGFR) mutations or anaplastic lymphoma
kinase (ALK) translocations. About 25% of patients with
advanced NSCLC have tumors with high levels of PD-L1
expression (PD-L1 expressed on ≥50% of tumor cells).
Pembrolizumab was approved earlier for treatment...
Guselkumab (Tremfya) for Psoriasis
The Medical Letter on Drugs and Therapeutics • Nov 06, 2017 (Issue 1533)
— No clinically significant
drug interactions have been reported with use
of guselkumab, but blocking IL-23 ...
The FDA has approved the interleukin (IL)-23 blocker
guselkumab (Tremfya – Janssen) for treatment of
moderate to severe plaque psoriasis in adults who
are candidates for systemic therapy or phototherapy.
Guselkumab is the first selective IL-23 blocker to
become available in the US.